Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors

NCT06258330 | Completed Phase 1 DMC

• 1 other identifier: AM003-FIH-001
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 5

Brief Summary

This is a phase 1, first-in-human study to assess the safety and tolerability of AM003 in patients with locally advanced and metastatic solid tumors

Conditions

Solid Tumor

Keywords

Phase 1; Dose escalation; Personalized treatment

Outcome Measures

Primary Outcomes (2)

• Number of SAEs, TEAEs assessed by CTCAE v.5.0

  First 28 days of treatment

• Number of TEAEs meeting protocol defined DLT criteria

  Number and percent of participants experiencing dose-limiting toxicities (DLTs), Grade 3 non-hematological adverse AEs, Grade 4 hematological AEs, and discontinuations of study drug due to AE intolerance.

  First 28 days of treatment

Secondary Outcomes (4)

• Number of participants responding to treatment by RESICT 1.1 criteria

  Duration of the study, estimated to be 6 months

• Number of participants responding to treatment by iRECIST criteria

  Duration of the study, estimated to be 6 months

• AM003 PK parameters - Cmax

  First 5 weeks of treatment

• AM003 PK parameters - AUC

  First 5 weeks of treatment

Study Arms (3)

Cohort 1 - low dose

EXPERIMENTAL

AM003 34 mg

Drug: AM003

Cohort 2 - mid dose

EXPERIMENTAL

AM003 68 mg

Drug: AM003

Cohort 3 - high dose

EXPERIMENTAL

AM003 136 mg

Drug: AM003

Interventions

AM003 DRUG

Bispecific Personalized Aptamer for intratumoral administration

Cohort 1 - low dose; Cohort 2 - mid dose; Cohort 3 - high dose

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 years at the time of signing the informed consent.
• Capable of providing signed informed consent, which includes compliance with the requirements of this protocol.
• Participants with histologically confirmed locally advanced/metastatic solid tumors who received and progressed after or were intolerant to at least 1 prior systemic therapy (unless no Standard of Care therapy exists) and are not candidates for any therapy known to confer clinical benefit.
• Eligible for recruitment are participants with a variety of solid tumors such as:
• Head and neck cancers
• Thyroid cancers
• Soft tissue sarcoma
• Colorectal cancers
• Skin (melanoma and non-melanoma),
• other cancer indications may be considered, but require sponsor approval NOTE: prior exposure to PD-1 or PDL-1 inhibitors are permitted.
• Lesions that are amenable to IT injection (by visual inspection, palpation, ultrasound or CT guidance). At least one measurable lesion must be amenable to both IT injection and biopsy. A measurable distant, discrete lesion that is also amenable to biopsy is optional.
• All participants must have measurable disease as defined by RECIST 1.1. Measurable disease is defined as at least one lesion that can be accurately measured by computed tomography (CT), magnetic resonance imaging (MRI), or caliper measurement by clinical exam, in at least one dimension (longest diameter to be recorded).
• For cohort 1 (dose level 1) participant must have at least one lesion ≥ 1.5 cm 5.2. For cohorts 2 and 3 (dose levels 2\&3), participant should preferably have at least one lesion ≥ 2.5cm and ≥ 5cm for cohorts 2 and 3 respectively. For cases in which no such single lesion can be identified, the total dose of AM003 may be split among several lesions or between a lesion and local SC administration(s).
• Personalized AM003 sequence identified for the participant during the pre-screening period or previous related studies.
• Eastern Cooperative Oncology Group (ECOG) performance status score ≤1.

You may not qualify if:

• Clinical evidence of active central nervous system (CNS) disease NOTE: Participants are eligible if brain metastases are adequately treated and participants are neurologically stable (except for residual signs or symptoms related to the central nervous system (CNS) treatment) for at least 2 weeks prior to enrollment without the use of corticosteroids or are on a stable or decreasing dose of≤ 10 mg daily prednisone (or equivalent)
• History of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months prior to the first date of study treatment.
• Participants with congestive heart failure (≥NYHA class 3) or unstable angina pectoris.
• Active, known or suspected autoimmune disease. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
• Condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses \< 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
• Prior severe hypersensitivity reaction to treatment with a monoclonal antibody
• Has not fully recovered from any effects of major surgery, and be free of significant detectable infection. Surgeries that required general anesthesia must be completed at least 2 weeks before first study drug administration. Surgery requiring regional/epidural anesthesia must be completed at least 72 hours before first study drug administration and participants should be recovered.
• History of organ transplant.
• Any Serious illness, uncontrolled inter-current illness, psychiatric illness, active of uncontrolled infection or other medical history, including laboratory results, which, in the opinion of the Investigator, would preclude the participant from adhering to the protocol or would increase the risk associated with study participation or study drug administration or interfere with the interpretation of study results.
• Participant received other investigational therapy, definitive radiation within 2 weeks, immunotherapy or treatment with anticancer medications within 28 days or at least 5 half-lives prior to the first dose of treatment, whichever is less.
• Participant is currently not recovered to baseline or CTCAE Grade 1 from the AEs due to cancer therapeutics administered more than 28 days prior to the first dose of treatment except for alopecia and peripheral neuropathy
• Pregnant or breastfeeding women.

Sponsors & Collaborators

• Aummune Ltd.: lead

Study Sites (5)

Rambam Health Care Campus

Haifa, Israel

Location

Hadassah Medical Center

Jerusalem, Israel

Location

Rabin Medical Center

Petah Tikva, 49100, Israel

Location

Sheba Medical Center

Ramat Gan, Israel

Location

Tel Aviv Sourasky Medical Center

Tel Aviv, Israel

Location

Study Officials

• Irit Carmi Levy, PhD

  GM and Chief Scientific Officer Aummune

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Dose Escalation

Study Record Dates

• First Submitted: June 1, 2022
• First Posted: February 14, 2024
• Study Start: June 22, 2022
• Primary Completion: July 7, 2024
• Study Completion: October 1, 2024
• Last Updated: January 28, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will not share

Locations

IL (5)